Comparing 2 methods of HBV vaccination in HIV positive patients

Not Applicable

• Conditions: Human Immunodeficiency Virus.; Asymptomatic human immunodeficiency virus [HIV] infection status- Viral vaccines; Z21-Y59.0

• Registration Number: IRCT2013122415878N2
• Lead Sponsor: Pasteur Institute of Iran

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

HIV positive adults referring to Iranian research center for HIV/AIDS with negative hepatitis B markers (HBsAg, anti-HBc, anti-HBs), no history of HBV vaccination, CD4 count more than 200 cells/mm3 and negative pregnancy test.

Exclusion criteria: Patients with immunosuppression (not related to HIV) like organ recipients, chemotherapy, using systemic steroids, hemopathy, cancer, opportunistic infection, splenectomy, renal failure, cases receiving other vaccines 1 month before study

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HBV vaccination. Timepoint: 1 and 4 months after the last dose of HBV vaccine. Method of measurement: checking of anti-HBs titre.